reports
CIC39 Corporation: 1 director
A director at CIC39 Corporation maiden bought 101,600 shares at 0.000VND and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
ParaZero Develops Counter Drone Solutions Leveraging Its Unique Techno...
ParaZero Develops Counter Drone Solutions Leveraging Its Unique Technology The counter unmanned aircraft system (C-UAS) market is estimated to reach over $15 billion by 2032 Tel Aviv, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "Company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones and urban air mobility aircraft, recently announced its intention to enter the counter unmanned aircraft system (C-UAS or anti-drone) market, by developing dedicated solutions based on its advanced techn...
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annu...
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological posters MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical candidate, PH-762, an INTASY...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 202...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time ...
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-...
Standard Uranium Reports on Recent Exploration Insights at the Sun Dog...
Standard Uranium Reports on Recent Exploration Insights at the Sun Dog Project with Option Partner Aero Energy Ltd. Sun Dog is host to globally significant former uranium producer. VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Standard Uranium Ltd. (“Standard Uranium” or the “Company”) (TSX-V: STND) (OTCQB: STTDF) (Frankfurt: FWB:9SU) is pleased to provide a comprehensive summary of exploration insights and historical data gathered at its Sun Dog Uranium Project (“Sun Dog”, or the “Project”), currently under a three-year earn-in option agreement with Aero Energy Ltd. (...
Osisko Metals Reports Preliminary Metallurgical Testwork Results From ...
Osisko Metals Reports Preliminary Metallurgical Testwork Results From Gaspé Copper MONTREAL, April 16, 2024 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") (; ; ) is pleased to announce preliminary metallurgical and grindability testwork results from the Gaspé Copper Project located near Murdochville in the Gaspé peninsula in Québec. Testwork was performed on eighteen composite samples of mineralized drill core from selected intersections of the 2023 drill program at Copper Mountain, and employed a conventional copper-molybdenum flotation flowsheet and r...
Métaux Osisko dévoile les résultats préliminaires des essais métallurg...
Métaux Osisko dévoile les résultats préliminaires des essais métallurgiques sur le gîte de cuivre de Mines Gaspé MONTRÉAL, 16 avr. 2024 (GLOBE NEWSWIRE) -- Métaux Osisko Incorporée (la « Société » ou « Métaux Osisko ») (; ; ) a le plaisir d'annoncer les résultats préliminaires des essais métallurgiques et de broyabilité du projet de cuivre de Mines Gaspé, situé près de Murdochville, dans la péninsule gaspésienne, au Québec. Les essais ont été effectués sur dix-huit échantillons composites de carottes de forage minéralisées provenant d'intersections sélectionnées dans le cadre du programm...
Lilium Starts Production of High-Performance Battery Packs for the Lil...
Lilium Starts Production of High-Performance Battery Packs for the Lilium Jet Lilium’s battery packs are being designed to meet the highest aviation safety standards First units off the battery assembly line at Lilium’s headquarters will be used for verification testing ahead of first piloted flight of the revolutionary Lilium Jet, targeted for end of 2024This follows several years of extensive testing of battery pack subcomponents from individual cell to stack level with a focus on performance, safety and regulatory conformityEach Lilium Jet will be fitted with 10 independent battery packs...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an A...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company’s AAVrh.10hFXN-based gene therapy candidate for the treatment of F...
Enovix Announces Fab2 Manufacturing Milestones
Enovix Announces Fab2 Manufacturing Milestones FREMONT, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it has completed Factory Acceptance Testing (“FAT”) for its Gen2 Agility Line and is on track to produce first silicon battery samples from Fab2 in the second quarter of 2024. “I’m proud to announce the team has completed our rigorous FAT process for all machines that make up our Agility Line,” said Ajay Marathe, Chief Operating Officer at Enovix. “SAT is also well underway. Both FAT and SAT processes ens...
- Pelham Smithers
PSA Media & Technology: Koei Tecmo (3635 JT) Revises Down
Koei Tecmo (3635 JT) slashed its FY23 (Mar yr-end) OP forecast to ¥27bil from ¥37.5bil, but has raised its NP forecast to ¥32bil from ¥31bil, due to a stronger-than-expected performance from the non-operating account. Pelham Smithers discusses.
Truth Social to Launch Streaming Platform
Truth Social to Launch Streaming Platform TMTG finishes R&D on its own content delivery network, announcing plans for phased streaming introduction SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Trump Media & Technology Group Corp. (NASDAQ:DJT) (“TMTG” or the “Company”), operator of the social media platform Truth Social, announced today that after six months of testing on its Web and iOS platforms, the Company has finished the research and development phase of its new live TV streaming platform and will begin scaling up its own content delivery network (“CDN”). TMTG plans to r...
Pineapple Resources Berhad: 1 director
A director at Pineapple Resources Berhad bought 266,950 shares at 0.700MYR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
TC Energy to issue first quarter 2024 results on May 3 and hold annual...
TC Energy to issue first quarter 2024 results on May 3 and hold annual and special meeting of common shareholders on June 4 CALGARY, Alberta, April 16, 2024 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will release its first quarter 2024 financial results on Friday, May 3, 2024 pre-market and hold its 2024 annual and special meeting of common shareholders on Tuesday, June 4, 2024, at 8 a.m. MDT / 10 a.m. EDT. First quarter 2024 financial resultsFrançois Poirier, TC Energy President and Chief Executive Officer, Joel Hunter, Executive Vice-President...
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics Provides SAB-142 Trial Update MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of serum sickness thus far. In October 2023, SAB rec...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targe...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver....
- Virginia Romero
NATURGY: CRITERIA CONFIRMA QUE MANTIENE CONVERSACIONES CON UN POTENCIA...
Criteria Caixa, en reacción a los rumores de esta mañana que apuntaban a que un grupo emiratí (Adnoc) estaría negociando la compra del 40% del capital de NTGY en manos de GIP y CVC, ha comunicado a la CNMV que reafirma su compromiso como inversor a largo plazo con el proyecto industrial de NTGY
Director/PDMR Shareholding
Director/PDMR Shareholding TORONTO, ONTARIO, April 16, 2024 (GLOBE NEWSWIRE) -- (“Amaroq Minerals” or the “Company”) Director/PDMR Shareholding - Notification of Transactions of Directors/Persons Discharging Managerial Responsibilities (PDMRs) TORONTO, ONTARIO – April 16, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ) announces that on April 15, 2024, it was informed that Livermore Partners LLC, a company in which David Neuhauser, Non-Executive Director of Amaroq Minerals, is Managing Director, acquired a total of 19,200 common shares of no par value in the Company. This ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.